CG Products Bucket

  1. Powering Production Of Viral Vector-Based Therapies 11/14/2025

    Gene therapies hold immense potential to provide long-lasting treatments for a wide range of diseases. At Cytiva, we offer GMP-compliant, end-to-end manufacturing solutions designed to support the development and commercialization of advanced medicines across multiple modalities – including AAV, adenovirus (AV), lentivirus (LV), plasmid DNA (pDNA) and exosomes. Our dependable suite of technologies and expertise ensures scalability, quality, and regulatory confidence at every stage of your journey.

  2. Automated, Single-Use Systems For TFF At Multiple Scales 11/7/2025

    Platform of automated, single-use systems for tangential flow filtration at multiple scales.

  3. Xcellerex™ X-Platform Bioreactors: A Next-Generation Single-Use Bioreactor System 11/6/2025

    Accelerate your gene therapy manufacturing with the Xcellerex™ X-platform – a next-generation single-use bioreactor system designed for viral vector workflows.

  4. Optimize Your Cell Line Strategy For Better Viral Vector Production 11/6/2025

    Optimize your cell line strategy for better viral vector production.

  5. HyClone™ Cell Culture Media For Viral Vector Production 11/6/2025

    Whether you're looking to boost performance, enhance your capabilities, or simply get consistent, high-quality results, HyClone™ peak expression medium and HyClone™ prime expression medium are the solutions for you.

  6. Small-Scale GMP Manufacturing With ÄKTA ready™ Chromatography System 450 11/6/2025

    ÄKTA ready™ chromatography system 450 is a single-use liquid chromatography system.

  7. LevMixer™ 10 L Single-Use Mixing System 11/6/2025

    The LevMixer™ 10 L single-use mixing system is a low volume mixer designed for both upstream and downstream applications.

  8. iCELLis™ Single-Use Fixed-Bed Bioreactor Systems 11/6/2025

    The iCELLis™ bioreactor system is an automated, single-use, fixed-bed bioreactor that provides excellent cell growth conditions for adherent cells.

  9. Achieve Efficient Viral Vector Production At Any Phase 10/28/2025

    The Challenge: Building Scalable Viral Vector Programs

    Cell and gene therapies offer unprecedented hope for previously untreatable diseases. At the heart of many of these advanced therapies, including both gene therapies and gene-modified cell therapies, are viral vectors, particularly Adeno-Associated Vectors (AAV) and Lentiviral Vectors (LVV), which serve as crucial gene-delivery vehicles.

  10. Power Your Gene Therapy Pipeline With A Proven AAV CDMO Partner 10/17/2025

    With 30+ years of experience in viral vector development and manufacturing, we bring unmatched expertise as your trusted CDMO for AAV. From plasmids to fill/finish and advanced analytics, we provide true end-to-end support, accelerating your path to the clinic and beyond.